Navigation Links
Cempra, Inc. Reports First Quarter 2013 Financial and Operating Results
Date:4/25/2013

mpra.com, and will be archived there for 30 days following the call. Please visit Cempra's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Cempra, Inc.Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are in advanced clinical development; solithromycin in Phase 3 for CABP and TAKSTA™ (CEM-102) in Phase 2 for prosthetic joint infections. Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others:  the costs, timing, regulatory review and results of our studies and clinical trials; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our ability to obtain FDA approval of our product candidates; our dependence on the success of solithromycin and Taksta; our anticipated capital expenditures and our estimates regarding our capital requirements; the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; the unpredictability of the size of the markets fo
'/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference
2. Cempra, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013
3. Cempra, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference
4. Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
5. Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
6. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
7. Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
8. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
9. Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results
10. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
11. Cempra, Inc. to Report Second Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on August 8, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... octreotide capsules for the orphan condition acromegaly, today ... June 30, 2015 and provided a corporate update. ... a transformative time for Chiasma, as we successfully ... that our first New Drug Application (NDA) has ...
(Date:8/31/2015)... 2015 A new Transparency ... monitoring and diagnostic devices market stood at US$3.7 ... a value of approximately US$7.0 billion in 2019, ... and 2019. The title of the report is ... Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, Implantable Loop ...
(Date:8/31/2015)... YORK , Aug. 31, 2015  Dipexium Pharmaceuticals, ... focused on the development and commercialization of Locilex® (pexiganan ... today announced plans to participate in four investor conferences ... 2, 2015 at the Sidoti & Company, LLC Emerging ... . David P. Luci , President & ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... announces the appointment of Susan C. Stansfield, PhD ... Development. In this position, Dr. Stansfield will have ... clinical trial management services provided to the biopharmaceutical ... proven leadership skills will be pivotal in enhancing ...
... Reportlinker.com announces that a new market research ... E7: The Outlook for Pharmaceuticals to ... The emerging E7 countries represent the ... these countries is huge: they have a ...
Cached Medicine Technology:Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development 2E7: The Outlook for Pharmaceuticals to 2012 2E7: The Outlook for Pharmaceuticals to 2012 3E7: The Outlook for Pharmaceuticals to 2012 4E7: The Outlook for Pharmaceuticals to 2012 5
(Date:9/1/2015)... Calif. (PRWEB) , ... September 01, 2015 , ... ... today that Brent Nelson, D.O., has joined its medical management team as an ... serving companies of all sizes and types in the U.S. and abroad. ...
(Date:9/1/2015)... , ... September 01, 2015 , ... SC&H Group, a ... which includes being named a “Best of the Best” firm in the U.S., as ... named the “Best of the Best” in the U.S., selected exclusively on performance in ...
(Date:9/1/2015)... ... ... Mercy Health (formerly Catholic Health Partners) – a Catholic healthcare ministry serving Ohio ... Be Well videos to prostate cancer awareness. Prostate cancer is the most-common, non-skin cancer ... Mercy Health’s YouTube channel, Mercy Health experts address issues, such as:, ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... its consumer-friendly, informational video this week to coincide with back-to-school and the start ... , According to the CDC, elementary school children are sick an average of ...
(Date:9/1/2015)... ... September 01, 2015 , ... Dr. Trace Curry successfully placed one of ... In the last month the FDA has approved two intra-gastric balloons, the ORBERA ... represent the first incisionless, reversible, weight loss procedures available to Americans. , ...
Breaking Medicine News(10 mins):Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2
... New data pooled from four large, "real world" ... VIII (rFVIII-FS) reduced bleeding and provided data regarding ... mild-to-severe hemophilia A. Additionally, rates of inhibitor formation ... untreated patients. The data were presented at the ...
... , SAN DIEGO, July 13 Victory Pharma, ... (FDA) has accepted for review the New Drug Application (NDA) for ... patients and healthcare providers the advantage of a proven antiemetic agent ... nausea and vomiting. , , "Acceptance ...
... July 13 Uroplasty, Inc. (NYSE Amex: ... and markets innovative proprietary products for the treatment of ... Patent No. 7,536,226 entitled, "Electro-Nerve Stimulator System and Methods." ... stimulation methods for treatment of the overactive bladder ("OAB") ...
... PORT WASHINGTON, N.Y., July 13 Premier Heart, LLC today ... Association has granted a CPT Category III code to Premier ... is the World,s first Internet based, non-invasive, stress, radiation and ... The MCG is intended as an aid for bridging ...
... 13 With summer in full swing, women everywhere are ... to the salon for manicures and pedicures. Starting this month, ... you look great has an added bonus - it ... , Today, Look Good...Feel Better , ...
... ... ... announces updates to its Website, www.prenexa.com . PreNexa® is the first single capsule prenatal ... a day.(1-4) , ,The updated content and offerings on prenexa.com include: , ...
Cached Medicine News:Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 2Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 3Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 4Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 5Health News:Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review 2Health News:Uroplasty Announces Patent Issuance Related to the Urgent(R) PC System 2Health News:Uroplasty Announces Patent Issuance Related to the Urgent(R) PC System 3Health News:AMA Grants New Category III CPT Code to Premier Heart's Multifunction CardioGram(TM) (MCG) 2Health News:Look Good...Feel Better and OPI Celebrate 20 Years of Helping Women Cope With Cancer 2Health News:Upsher-Smith Laboratories, Inc. Updates Prenexa.com with Folic Acid Content, Money-Saving Coupon, and Personalized Address Labels 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: